Letters by company
IAC Inc.
1 letter discussing IAC. Everything written about it on this site is on its ticker page.
- Patient Capital Management 3Q25 Portfolio Recap Patient Opportunity Equity Strategy converted and trimmed Precigen after Papzimeos won early FDA approval, while retaining conviction in its commercial opportunity and pipeline. The strategy added aggressively to UnitedHealth during its sell-off and increased selected laggards including Crocs, Mattel, IAC and Biogen while keeping exposure to momentum areas. 3Q25 +14.1% PGEN $2.6BUNH $350BBIIB $33BCROX $5.9B
